Inhibition of CXCR4 significantly enhances sensitivity of hepatoma cells to sorafenib [52, 53], while high CXCR4 expression correlates with poor response upon sunitinib treatment for metastatic RCC [54, 55]. Here, CXCR4 is linked to hepatocellular carcinoma.